Pfizer Inc. said a landmark study of its pneumonia vaccine met
primary and secondary endpoints, showing the ability to reduce
first episodes of several kinds of pneumonia.
Prevenar 13, Pfizer's pneumonia vaccine, was able to prevent
first episodes of vaccine-type community-acquired pneumonia--or
pneumonia spread through normal social contact--in adults 65 years
or older, the drug maker said Wednesday.
During the trial, there were nearly 46% fewer first episodes of
the pneumonia in patients treated with Prevenar 13 versus those who
received a placebo.
Pfizer said the trial is the first in adults to clearly
demonstrate a significant reduction in vaccine-type pneumococcal
pneumonia.
The trial, which studied 85,000 subjects, also significantly
reduced nonbacteremic/noninvasive vaccine-type pneumococcal
pneumonia and vaccine-type invasive pneumococcal disease.
"With the aging of the population, hospitalizations due to
pneumococcal pneumonia represent a growing burden to public health
systems. Evidence from this study is particularly important for a
population in which age-related decline of the immune system makes
it difficult to prevent disease," said Dr. Emilio A. Emini, senior
vice president, Vaccine Research and Development, Pfizer.
Prevenar 13 was licensed by the U.S. Food and Drug
Administration in 2011 under an accelerated approval process to
address an unmet medical need in older adults, Pfizer said.
Write to Everdeen Mason at everdeen.mason@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires